GSK Raises Guidance on Strong Sales of Arexvy Vaccine

British pharmaceuticals company GSK (ticker GSK) raised its outlook for the second time this year, pushing shares higher in early trading Wednesday. GSK has been lifted by sales of its recently launched Arexvy vaccine that prevents a common respiratory disease. Operating profit increased 15% in the third quarter from a year earlier, though the gains were offset by research investment, new product launches and lower Covid-19 medicine sales.